From the Liver Unit, Meyer Children's University Hospital, University of Florence, Florence, Italy.
the Department of Medicine and Surgery, University of Parma, Parma, Italy.
J Pediatr Gastroenterol Nutr. 2022 Aug 1;75(2):e2-e7. doi: 10.1097/MPG.0000000000003481. Epub 2022 Jun 1.
To prospectively describe the epidemiology and long-term outcome of childhood-acquired hepatitis C virus (HCV) infection in a large cohort of children followed at a single center.
All children with chronic HCV infection followed at the Liver Unit of our tertiary Hospital in Florence (Italy) from January 1, 1988, to September 30, 2021, were included in the analysis.
The final sample consisted of 163 children (median age at enrollment 4 years, interquartile range (IQR): 10; median age at last follow-up 14 years, IQR: 7). The median duration of follow-up was 86 months (IQR: 112). One hundred twenty-five children were vertically infected and 26 acquired the infection horizontally. Twenty-six of the 125 children who were vertically infected (20.8%) underwent spontaneous clearance of HCV RNA at a median age of 4 years (IQR: 2), whereas all the others remained persistently viremic. One patient was diagnosed with cirrhosis; 2 presented clinically detectable extrahepatic manifestations (chronic urticaria). Thirty-two children (19.6%) received antiviral therapy: 8 out of 32 (25%) were treated with pegylated-interferon alfa-2b [sustained virological response (SVR) 24 weeks after the end of treatment in 7/8]; 24 out of 32 (75%) were treated with direct-acting antivirals (SVR 12 weeks after the end of treatment in 23/24).
The present study describes the largest cohort of children with chronic HCV infection prospectively evaluated with a long follow-up at a single center. HCV infection in children is often a chronic infection that can be cured with modern antiviral therapy. Early treatment could prevent the development of advanced liver disease.
前瞻性描述在一家单中心接受治疗的大型儿童队列中,儿童获得性丙型肝炎病毒 (HCV) 感染的流行病学和长期结局。
纳入自 1988 年 1 月 1 日至 2021 年 9 月 30 日在意大利佛罗伦萨的肝脏科接受治疗的所有慢性 HCV 感染儿童。
最终样本包括 163 名儿童(入组时的中位年龄为 4 岁,四分位距(IQR):10;最后一次随访时的中位年龄为 14 岁,IQR:7)。中位随访时间为 86 个月(IQR:112)。125 名儿童为垂直感染,26 名儿童为水平感染。在 125 名垂直感染的儿童中,26 名(20.8%)在中位年龄为 4 岁(IQR:2)时自发清除 HCV RNA,而其余儿童均持续病毒血症。1 名患者被诊断为肝硬化;2 名患者出现临床可检测到的肝外表现(慢性荨麻疹)。32 名儿童(19.6%)接受了抗病毒治疗:8 名儿童(25%)接受了聚乙二醇干扰素 alfa-2b 治疗[治疗结束后 24 周时获得持续病毒学应答(SVR)8/8];24 名儿童(75%)接受了直接作用抗病毒药物治疗[治疗结束后 12 周时获得 SVR 23/24]。
本研究描述了在一家单中心接受前瞻性评估并进行长期随访的最大儿童慢性 HCV 感染队列。儿童 HCV 感染通常为慢性感染,可通过现代抗病毒治疗治愈。早期治疗可预防晚期肝病的发生。